Hemogenyx Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: HOPH.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HOPH.F?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	8,700	0.162%
Private Companies	49,641	0.926%
Individual Insiders	854,191	15.9%
General Public	896,636	16.7%
Institutions	3,552,099	66.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.8%.

Top Shareholders

Top 25 shareholders own 82.5% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
19.3%	Hargreaves Lansdown Asset Management Ltd.	1,032,028	US$13.4m	12.2%	0.03%
14.2%	Aberdeen Group Plc	759,977	US$9.9m	23.7%	0.01%
9.55%	HBOS Investment Fund Managers Limited	512,082	US$6.7m	9.31%	0.04%
8.74%	Barclays Bank PLC	468,676	US$6.1m	20.3%	0.01%
7.84%	Vladislav Sandler	420,528	US$5.5m	-30.4%	no data
7.78%	IG Group Holdings plc	417,200	US$5.4m	12.6%	0.35%
4.33%	David Smith	231,948	US$3.0m	0%	no data
3.5%	Alexis Sandler	187,726	US$2.4m	0%	no data
2.87%	HSBC Global Asset Management (UK) Limited	153,779	US$2.0m	1.26%	no data
0.53%	43North LLC	28,428	US$369.7k	0%	no data
0.52%	Prevail Partners	27,666	US$359.8k	0%	100.0%
0.47%	Raymond James Wealth Management Limited	25,103	US$326.5k	28.8%	no data
0.32%	Equiniti Group Limited	16,997	US$221.1k	3.63%	no data
0.32%	Fidelity International Ltd	16,946	US$220.4k	-19.1%	no data
0.28%	Integrated Financial Arrangements plc	15,119	US$196.6k	24.4%	0.01%
0.27%	GHC Property Services Limited	14,587	US$189.7k	0%	no data
0.26%	Peter Redmond	13,989	US$181.9k	11%	no data
0.26%	Copier Systems Limited	13,891	US$180.7k	0%	no data
0.24%	James Brearley & Sons Ltd.	12,899	US$167.8k	-18.2%	0.06%
0.23%	Canaccord Genuity Wealth (International) Ltd.	12,341	US$160.5k	0%	no data
0.21%	UBS Asset Management AG	11,480	US$149.3k	-19.6%	no data
0.18%	Merrill Lynch, Pierce, Fenner & Smith Incorporated	9,433	US$122.7k	0%	no data
0.14%	eToro (UK) Ltd.	7,634	US$99.3k	6.07%	0.06%
0.12%	GHC Capital Markets Ltd.	6,238	US$81.1k	0%	0.19%
0.12%	Lloyds Banking Group plc	6,200	US$80.6k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/20 10:23
End of Day Share Price	2025/07/23 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.